Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
3.440
-0.090 (-2.55%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Galectin Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 13.27 | 17.72 | 15.12 | 25.66 | 18.59 | 39.65 |
Cash & Short-Term Investments | 13.27 | 17.72 | 15.12 | 25.66 | 18.59 | 39.65 |
Cash Growth | -3.65% | 17.20% | -41.08% | 38.02% | -53.11% | 46.08% |
Prepaid Expenses | 1.39 | 1.71 | 2.13 | 2.04 | 1.95 | 2.17 |
Other Current Assets | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Total Current Assets | 14.66 | 19.44 | 17.25 | 27.71 | 20.55 | 41.82 |
Property, Plant & Equipment | 0.12 | 0.02 | - | 0.05 | 0.09 | - |
Other Long-Term Assets | 0.05 | 0.07 | 0.24 | 0.44 | 0.65 | 0.01 |
Total Assets | 14.83 | 19.53 | 17.5 | 28.2 | 21.29 | 41.83 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.73 | 3.25 | 5.66 | 6.43 | 3.89 | 1.81 |
Accrued Expenses | 3.93 | 4.7 | 8.19 | 9.14 | 9.02 | 7.16 |
Current Portion of Long-Term Debt | 143.84 | - | 21.49 | - | - | - |
Current Portion of Leases | 0.06 | 0.02 | 0.02 | 0.05 | 0.04 | 0.01 |
Other Current Liabilities | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 |
Total Current Liabilities | 151.62 | 8.03 | 35.41 | 15.68 | 13.01 | 9.03 |
Long-Term Debt | - | 137.7 | 85.16 | 72.75 | 39.83 | 29.05 |
Long-Term Leases | 0.06 | - | - | 0.02 | 0.07 | - |
Other Long-Term Liabilities | - | - | - | - | 0.57 | 1.13 |
Total Liabilities | 151.68 | 145.73 | 120.57 | 88.44 | 53.48 | 39.21 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.07 | 0.07 | 0.06 | 0.06 | 0.06 | 0.06 |
Additional Paid-In Capital | 307.67 | 304.07 | 296.22 | 291.85 | 275.08 | 271 |
Retained Earnings | -446.79 | -432.55 | -401.57 | -354.37 | -309.57 | -270.69 |
Total Common Equity | -139.06 | -128.41 | -105.29 | -62.46 | -34.43 | 0.37 |
Shareholders' Equity | -136.85 | -126.2 | -103.07 | -60.24 | -32.19 | 2.62 |
Total Liabilities & Equity | 14.83 | 19.53 | 17.5 | 28.2 | 21.29 | 41.83 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 143.96 | 137.72 | 106.66 | 72.81 | 39.93 | 29.06 |
Net Cash (Debt) | -130.69 | -120 | -91.54 | -47.15 | -21.34 | 10.59 |
Net Cash Growth | - | - | - | - | - | -60.90% |
Net Cash Per Share | -2.01 | -1.88 | -1.47 | -0.78 | -0.36 | 0.18 |
Filing Date Shares Outstanding | 100.85 | 65.83 | 63.18 | 61.9 | 59.44 | 59.36 |
Total Common Shares Outstanding | 66.31 | 65.2 | 63.16 | 61.85 | 59.43 | 59.34 |
Working Capital | -136.96 | 11.41 | -18.16 | 12.03 | 7.54 | 32.79 |
Book Value Per Share | -2.10 | -1.97 | -1.67 | -1.01 | -0.58 | 0.01 |
Tangible Book Value | -139.06 | -128.41 | -105.29 | -62.46 | -34.43 | 0.37 |
Tangible Book Value Per Share | -2.10 | -1.97 | -1.67 | -1.01 | -0.58 | 0.01 |
Machinery | - | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
Leasehold Improvements | - | 0 | 0 | 0 | 0 | 0 |